Chronic CBD treatment did not improve behavioral symptoms in a tau-based Alzheimer's mouse model | Research

The takeaway

Three weeks of CBD treatment at 50 mg/kg did not reverse motor impairments, anxiety changes, or altered fear conditioning in a tau transgenic mouse model of Alzheimer's disease.

Alzheimer's researchers, neuroscientists studying CBD neuroprotection, and clinicians evaluating CBD for neurodegenerative conditions.

CBD did not reverse any behavioral deficit in tau transgenic mice

What the researchers found

TAU58/2 transgenic mice showed reduced body weight, reduced anxiety, impaired motor function, and increased freezing in fear conditioning compared to wildtype. Social recognition memory was intact. Chronic CBD (50 mg/kg i.p. for 3+ weeks) did not affect any behavioral measures in transgenic males.

Why it matters

While CBD has shown benefits in amyloid-based Alzheimer's mouse models, this study suggests it may not be equally effective in tau-based models, highlighting that Alzheimer's pathology type matters for treatment selection.

The numbers in context

50 mg/kg CBD administered i.p. daily. Started 3 weeks before behavioral testing. No significant effects on any behavioral measure in transgenic mice. TAU58/2 mice showed intact social recognition despite other deficits.

How the study worked

Open-label study of 4-month-old male TAU58/2 transgenic mice and wildtype controls. CBD (50 mg/kg) or vehicle administered intraperitoneally starting 3 weeks before behavioral testing. Assessed anxiety, motor function, fear conditioning, sociability, and social recognition.

What this study cannot tell us

Only one dose (50 mg/kg) and one administration route (i.p.) tested. Only male mice at one age (4 months). The mice may have been too young for full tau pathology to develop. No brain tissue analysis to confirm whether CBD reached relevant brain regions or affected tau levels.

How to read the evidence

Controlled preclinical study but limited by single dose, one time point, one sex, and no molecular analysis.

When this study was published

2020 animal study. Highlights pathology-specific limitations of CBD in Alzheimer's models.

The bigger picture

Alzheimer's disease involves both amyloid-beta and tau pathology. The failure of CBD in a tau model despite success in amyloid models suggests its neuroprotective mechanisms may be more relevant to amyloid than tau pathology.

Questions still open

Would higher CBD doses, longer treatment, or different timing be effective? Would CBD work in older TAU58/2 mice with more advanced pathology? Does CBD have any effect on tau phosphorylation or aggregation at the molecular level?

Common questions

Why did CBD work in other Alzheimer's models but not this one?

Previous positive results came from amyloid-based models. This study used a tau-based model (TAU58/2), suggesting CBD's neuroprotective mechanisms may target amyloid pathways more than tau pathways.

What is the TAU58/2 model?

TAU58/2 is a transgenic mouse model that overexpresses a mutant form of the tau protein, which forms the neurofibrillary tangles seen in Alzheimer's disease. These mice develop motor deficits and behavioral changes.

Read the original research

Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice.

Pharmacology, biochemistry, and behavior, 196, 172970

View on PubMed ↗Publisher’s paper ↗

Citation

Watt, Georgia; Chesworth, Rose; Przybyla, Magdalena; Ittner, Arne; Garner, Brett; Ittner, Lars M; Karl, Tim. (2020). Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice.. Pharmacology, biochemistry, and behavior, 196, 172970. https://doi.org/10.1016/j.pbb.2020.172970